Linifanib

Drugs in R and D

Volumn 10, Issue 2, 2010, Pages 111-122

[No Author Info available]

Author keywords

Breast cancer; Colorectal cancer; general; Linifanib; Liver cancer; Non small cell lung cancer; Research and development; treatment

Indexed keywords

A 741439; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; KETOCONAZOLE; LINIFANIB; OXALIPLATIN; PACLITAXEL; RG 3635; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VORINOSTAT;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASCITES; ASTHENIA; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CHEMOTHERAPY INDUCED EMESIS; CIRCADIAN RHYTHM; COLORECTAL CANCER; DEHYDRATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOOD DRUG INTERACTION; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; KIDNEY CARCINOMA; LEUKEMIA CELL; LIVER CANCER; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MONOTHERAPY; MOUTH DISEASE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHRECTOMY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; INDAZOLES; NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 79953176652     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11584520-000000000-00000     Document Type: Article

References (21)

1. Abbott, Genentech Inc. Abbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology. www.abbott.com, 26 Jun. 2007 Media Release
2. Rugo HS, Lopez-Hernandez J, Gomez-Villanueva A, et al. ABT-869 in Combination with Paclitaxel (P) as First-Line Treatment in Patients (Pts) with Advanced Breast Cancer. 32nd Annual San Antonio Breast Cancer Symposium: abstr. 5076, 10 Dec. 2009. Available from URL: http://www.sabcs.org/. USA. [English]
3. Toh H, Chen P, Carr BI, et al. Linifanib phase II trial in patients with advanced hepatocellular carcinoma. 46th Annual Meeting of the American Society of Clinical Oncology: abstr. 4038, 4 Jun. 2010. Available from URL: http://www.asco.org. Singapore. [English]
4. Soo RA, Goss GD, Salgia R, et al. Linifanib treatment in patients with non-small cell lung cancer (NSCLC): Phase II results. 46th Annual Meeting of the American Society of Clinical Oncology: abstr. 7590, 4 Jun. 2010. Available from URL: http://www.asco.org. Singapore. [English]. Clinical Trials Insight
5. Tan E, Salgia R, Besse B, et al. ABT-869 in non-small cell lung cancer: Interim results. 45th Annual Meeting of the American Society of Clinical Oncology: 425s abstr. 8074, 30 May 2009. Available from URL: http://www.abstract. asco.org. Singapore. [English]. Clinical Trials Insight
6. Tannir NM, Wong Y, Kollmannsberger CK, et al. Phase II trial of linifanib in patients with advanced renal cell cancer after sunitinib failure. 46th Annual Meeting of the American Society of Clinical Oncology: abstr. 4527, 4 Jun. 2010. Available from URL: http://www.asco.org. USA. [English]
7. Hernandez JE, Zape J, Glaser K, et al. Multi-targeted receptor tyrosine kinase inhibitor, ABT-869, induces apoptosis and suppresses proliferation of Ba/F3 FLT-3 ITD mutant cells in vitro and in vivo through inhibition of FLT3 and AKT. 50th Annual Meeting and Exposition of the American Society of Hematology: abstr. 1938, 7 Dec. 2008. Available from URL: http://www.hematology.org. USA. [English]
8. Humerickhouse R, Gupta N, Goh B, et al. Phase 1 comparison of pharmacokientics, safety and efficacy with low versus high doses of ABT-869 in refractory solid tumors. 33rd Congress of the European Society for Medical Oncology: abstr. 476P, 12 Sep. 2008. Available from URL: http://annonc. oxfordjournals.org. USA. [English]
9. Steinberg J, Tan E, Wei-Peng Y, et al. Preliminary analysis of ABT-869 safety, pharmacokinetics and efficacy in three phase 2 solid tumor studies. 33rd Congress of the European Society for Medical Oncology: abstr. 477P, 12 Sep. 2008. Available from URL: http://annonc.oxfordjournals.org. USA. [English]
10. Tamura T, Yamamoto N, Nokihara H, et al. A Phase 1 open-label study evaluating pharmacokinetics, safety, and tolerability of linifanib in Japanese patients with solid tumors. 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: abstr. C37, 15 Nov. 2009. Available from URL: http://www.aacr.org/home/scientists/meetings-workshops/molecular- targets-andcancer-therapeutics.aspx. Japan. [English]
11. Gupta N, Yan Z, Lo Russo P, et al. Assessment of the effect of food on the oral bioavailability and assessment of diurnal variation in the pharmacokinetics of linifanib. 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: abstr. B53, 15 Nov. 2009. Available from URL: http://www.aacr.org/home/scientists/meetings-workshops/molecular- targets-and-cancertherapeutics.aspx. USA. [English]. Clinical Trials Insight
12. Wong CI, Thng CH, Soo R, et al. Phase I and biomarker study of ABT869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. Journal of Clinical Oncology. 25 (Suppl.): 142, No. 18, Part 1, 20 Jun. 2007. Singapore. [English]
13. Goh BC, Thng CH, Sukri N, et al. Phase I study of ABT869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. EJC Supplements. 4:36, No. 12, Nov. 2006. Singapore. [English]
14. Goh BC, Wong C, Qian J, et al. Extended linifanib therapy in patients with advanced solid tumors in a phase I trial. 46th Annual Meeting of the American Society of Clinical Oncology: abstr. 3053, 4 Jun. 2010. Available from URL: http://www.asco.org. Singapore. [English]
15. Donawho CK, Bukofzer G, Ellis PA, et al. The broad spectrum antitumor efficacy and tolerability of the RTK inhibitor, linifanib (ABT-869) alone and in combination with various cytotoxic therapies. 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: (plus poster) abstr. B14, 15 Nov. 2009. Available from URL: http://www.aacr.org/home/scientists/ meetings-workshops/molecular-targets-and-cancer-therapeutics.aspx. USA. [English]
16. Shankar DB, Chang JC, Parcells B, et al. The multi-targeted receptor tyrosine kinase inhibitor, ABT-869, induces apoptosis of AML cells both in vitro and in vivo. Blood. 106:183, No. 11, Part 1, 16 Nov. 2005. USA. [English]
17. Zhou J, Bi C, Liu S-C, et al. Identification of core gene signature associated with synergism between ABT-869, a FLT3 inhibitor and SAHA, a HDAC inhibitor in AML with FLT3-ITD mutation. 50th Annual Meeting and Exposition of the American Society of Hematology: abstr. 1618, 6 Dec. 2008. Available from URL: http://www.hematology.org. Singapore. [English]
18. Li J, Pease LJ, Tapang P, et al. ABT-869, a novel multitargeted receptor tyrosine kinase inhibitor: characterization of FLT3 phosphorylation in a model of acute myelogenous leukemia. 96th Annual Meeting ofthe American Association for Cancer Research. 46:1407 (plus poster) abstr. 5981, Apr. 2005. USA. [English]
19. Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869, a multi-targeted receptor tyrosine kinase inhibitor. 96th Annual Meeting of the American Association for Cancer Research. 46:159-160, Apr. 2005. USA. [English]
20. Guo J, Dai Y, Bui MH, et al. Cellular activity of ABT-869 against colony-stimulating-factor-1 receptor in macrophage-like cell lines. 100th Annual Meeting of the American Association for Cancer Research: abstr. 1789, 19 Apr. 2009. Available from URL: http://www.aacr.org. USA. [English]
21. Toh HC, Yong WP, Wong Y-N, et al. Phase 2 trials of linifanib (ABT-869) in advanced hepatocellular, renal cell and non-small cell lung cancer: Associations of response by CT or DCE-MRI with patient outcome. 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: (plus poster) abstr. A105, 15 Nov. 2009. Available from URL: http://www.aacr.org/home/scientists/meetings-workshops/molecular-targets-and- cancertherapeutics.aspx. Singapore. [English]